Increased Risk of Unfavorable Metabolic Outcome in Patients with Clinically Nonfunctioning Pituitary Adenomas

Abstract

The aim of this study was to investigate atherosclerotic risk markers in women with clinically nonfunctioning pituitary adenomas (CNFAs). Records of 47 women with CNFAs and 73 healthy women who were treated as outpatients between January 2010 and March 2014 were evaluated retrospectively. All study data were obtained from file records. Lipid parameters, mean platelet volume (MPV), total testosterone (TT), androstenedione (AS), and dehydroepiandrostenedione sulfate (DHEAS) were recorded. Insulin resistance (IR) was calculated with homeostatic model assessment-insulin resistance (HOMA-IR). Among the atherosclerotic risk markers, the HOMA-IR and AS levels were higher in patients with CNFAs than in healthy subjects (p=0.003, p=0.021, respectively). A positive correlation between AS and insulin/HOMA-IR levels was found among the metabolic parameters in the patients with CNFAs (p=0.001, r=0.550, p=0.004, r=0.498, respectively). The data showed that patients with CNFAs had high atherosclerotic risk markers such as insulin resistance and hyperandrogenemia. Insulin resistance may also cause hyperandrogenemia in patients with CNFAs.

Key words

androgens - atherosclerotic risk markers - clinically nonfunctioning pituitary adenomas

• References

• 1 Melmed S, Polonsky KS, Larsen PR, Kronenberg HM. (eds.). Williams Textbook of Endocrinology. 12^th edition Philadelphia, PA: Saunders Elsevier; 2011
• 2 Gardner David G, Shoback D. Lange Textbook of Endocrinology. 9^th edition 2011
• 3 Jiang XB, Li CL, He DS, Mao ZG, Liu DH, Fan X, Hu B, Zhu YH, Wang HJ. Increased carotid intima media thickness is associated with prolactin levels in subjects with untreated prolactinoma: a pilot study. Pituitary 2014; 232-239
• 4 Erem C, Kocak M, Nuhoglu I, Yılmaz M, Ucuncu O. Blood coagulation, fibrinolysis and lipid profile in patients with prolactinoma. Clin Endocrinol (Oxf) 2010; 73: 502-527
• 5 Wallaschofski H, Kobsar A, Sokolova O, Siegemund A, Stepan H, Faber R, Eigenthaler M, Lohmann T. Horm Differences in platelet activation by prolactin and leptin. Metab Res 2004; 36: 453-457
• 6 Arslan MS, Topaloglu O, Sahin M, Tutal E, Gungunes A, Cakir E, Ozturk IU, Karbek B, Ucan B, Ginis Z, Cakal E, Ozbek M, Delibasi T. Preclinical atherosclerosis in patients with prolactinoma. Endocrin Pract 2014; 20: 447-451
• 7 Mosca S, Paolillo S, Colao A, Bossone E, Cittadini A, Iudice FL, Parente A, Conte S, Rengo G, Leosco D, Trimarco B, Filardi PP. Cardiovascular involvement in patients affected by acromegaly: an appraisal. Int J Cardiol 2013; 167: 1712-1718
• 8 Lombardi G, Di Somma C, Grasso LF, Savanelli MC, Colao A, Pivonello R. The cardiovascular system in growth hormone excess and growth hormone deficiency. Endocrinol Invest 2012; 35: 1021-1029
• 9 Chanson P, Salenave S. Metabolic syndrome in Cushing’s syndrome. Neuroendocrinology 2010; 92: 96-101
• 10 De Leo M, Pivonello R, Auriemma RS, Cozzolino A, Vitale P, Simeoli C, De Martino MC, Lombardi G, Colao A. Cardiovascular disease in Cushing’s syndrome: heart versus vasculature. Neuroendocrinology 2010; 92: 50-54
• 11 Jellinger PS, Smith DA, FACE . Mehta AE, Ganda O, Handelsman Y, Rodbard HW, Shepherd MD, Seibel JA. American Association of clinical Endocrinologists guidelines for management of Dyslipidemia and prevention of Atherosclerosis. AACE Lipid and Atherosclerosis guidelines. Endocr Pract 2012; 18: 1
• 12 Kodiatte TA, Manikyam UK, Rao SB, Jagadish TM, Reddy M, Lingaiah HKM, Lakshmaiah V. Mean platelet volume in Type 2 diabetes mellitus. J Lab Physicians 2012; 4: 5
• 13 Tavil Y, Sen N, Yazici HU, Hizal F, Abaci A, Cengel A. Mean platelet volume in patients with metabolic syndrome and its relationship with coronary artery disease. Thromb Res 2007; 120: 245-250
• 14 Nechita A, Delcea C, Enache V, Ploesteanu RL, Cazacu C, Andronescu AM, Stroi AM, Stamate CS. Metabolic syndrome and mean platelet volume variation in patients with chest pain and negative cardiac enzymes. J Med Life 2013; 6: 156-160
• 15 Bath P, Algert C, Chapman N, Neal B. Group PC . Association of mean platelet volume with risk of stroke among 3134 individuals with history of cerebrovascular disease. Stroke 2004; 35: 622-626
• 16 Kebapcilar L, Taner CE, Kebapcilar AG, Sari I. High mean platelet volume, low-grade systemic coagulation and fibrinolytic activation are associated with androgen and insulin levels in polycystic ovary syndrome. Arch Gynecol Obstet 2009; 280: 187-193
• 17 Hatch R, Rosenfield RL, Kim MH, Tredway D. Hirsutism: implications, etiology, and management. Am J Obstet Gynecol 1981; 140: 815-830
• 18 Doğan BA, Tuna MM, Arduç A, Nasiroğlu Nİ, Tütüncü Y, Işik S, Yilmaz M, Berker D, Güler S. Mean Platelet Volume and Lipid Profile in Non-obese Prolactinoma Patients Without Insulin Resistance. Turkiye Klinikleri. J Endocrinol 2014; 9: 33-38
• 19 Gonzalez F, Sia CL, Bearson DM, Blair HE. Hyperandrogenism induces a proinflammatory TNFalpha response to glucose ingestion in a receptor-dependent fashion. J Clin Endocrinol Metab 2014; 99: E848-E854
• 20 Freda PU, Beckers AM, Katznelson L, Molitch ME, Montori VM, Post KD, Vance ML. Pituitary Incidentaloma: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2011; 96: 894-904
• 21 Wongwananuruk T, Rattanachaiyanont M, Leerasiri P, Indhavivadhana S, Techatraisa K. The Usefulness of HomeostaticMeasurement Assessment-Insulin Resistance (HOMA-IR) for Detection of Glucose Intolerance in ThaiWomen of Reproductive Age with Polycystic Ovary Syndrome. Int J Endocrinol 2012; Article ID 571035, 6 pages
• 22 Pabon JE, Li X, Lei ZM, Sanfilippo JS, Yussman MA, Rao CV. Novel presence of luteinizing hormone/chorionic gonadotropin receptors in human adrenal glands. J Clin Endocrinol Metab 1996; 81: 2397-2400
• 23 Marshall S, Kledzik GS, Gelato M, Campbell GA, Meites J. Effects of estrogen and testosterone on specific prolactin binding in the kidneys and adrenal of rats. Steroids 1976; 27: 187-195
• 24 O’Connell Y, McKenna TJ, Cunningham SK. The effect of prolactin, human chorionic gonadotropin, insulin and insulin-like growth factor 1 on adrenal steroidogenesis in isolated guinea-pig adrenal cells. J Steroid Biochem Mol Biol 1994; 48: 235-240
• 25 Hagag P, Hertzianu I, Ben-Shlomo A, Weiss M. Androgen suppression and clinical improvement with dopamine agonists in hyperandrogenic-hyperprolactinemic women. J Reprod Med 2001; 46: 678-684
• 26 Belisle S, Menard J. Adrenal androgen production in hyperprolactinemic states. Fertil Steril 1980; 33: 396-400
• 27 Green VL, Speirs V, Landolt AM, Foy PM, Atkin SL. 17β-Hydroxysteroid Dehydrogenase Type 1, 2, 3, and 4 Expression and Enzyme Activity in Human Anterior Pituitary Adenomas. J Clin Endocrinol Metab 1999; 84: 1340-1345
• 28 Shroff R, Syrop CH, Davis W, Van Voorhis BJ, Dokras A. Risk of metabolic complications in the new PCOS phenotypes based on the Rotterdam criteria. Fertil Steril 2007; 88: 1389-1395
• 29 Azziz R, Carmina E, Dewailly D, Diamanti-Kandarakis E, Escobar-Morreale HF, Futterweit W, Janssen OE, Legro RS, Norman RJ, Taylor AE, Witchel SF. The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report. Fertil Steril 2009; 91: 456-488